Clinical trials: Covid19 Positive Patient
SARS-CoV-2 Positive Patients
Follow-up Study of COVID-19 Patients in the District Konstanz
This is a prospective single-center study for the follow-up of SARS-CoV-2 positive patients in the district of Konstanz (LKN). As part of the coronavirus pandemic, patients with SARS-CoV-2 infection are currently being treated in…
- Trial name
- FSC19-KN (NCT04724434)
- Where
- Germany
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Hegau-Bodensee-Klinikum Singen
SARS-CoV Infection
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.
- Trial name
- NCT04327804
- Testing
- Odd/Even birth year intervention groups
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- UnitedHealth Group
Covid19, COVID-19
Tocilizumab in Coronavirus-19 Positive Patients
This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19.
- Conditions
- Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus
- Trial name
- NCT04423042
- Testing
- Tocilizumab
- Volunteers
- 30 people
- Sponsor
- University of Calgary
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04455958
- Testing
- Lopinavir/Ritonavir, Questionnaire Administration
- Sponsor
- OHSU Knight Cancer Institute
COVID-19
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives
Coronavirus disease 2019 (COVID-19) ,caused by the newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has shown substantial global spread affecting over 2 million people and claiming over 120,000…
- Trial name
- NCT04357535
- Testing
- Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
- Where
- Saudi Arabia
- Volunteers
- 314 people
- Sponsor
- Hakeam Abdulaziz Hakeam
Covid19
Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)
Breath analysis is the evaluation of exhaled air of humans. It aims to get information about the clinical status of a human being by monitoring its volatile organic compounds (VOCs) in exhaled air.
- Trial name
- NCT04556318
- Testing
- Ion Mobility Spectrometry (IMS)
- Where
- 2 sites in Germany
- Volunteers
- 396 people
- Sponsor
- B. Braun Melsungen AG
Virus Infection, RNA, Effect of Drug
Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx
The COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War-II.Corona virus is transmitted via respiratory droplets or aerosol, produced from sneezing or…
- Conditions
- Virus Infection, RNA, Effect of Drug, Efficacy, Self
- Trial name
- COVID-19 (NCT04872686)
- Testing
- 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient, 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity, 0.6% PVP-I Oral and nasal spray to healthy volunteer
- Where
- 4 sites in Bangladesh
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- DR. MALA KHAN
COVID-19 Patients
Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients
The clinical spectrum of COVID-19 can be very heterogeneous: from mild flu-like symptoms, to the form with severe pulmonary impairment (dyspnoea, tachypnoea, PaO2 / FiO2 ratio below 300 at arterial blood gas sampling, pulmonary…
- Trial name
- outcomes (NCT05162534)
- Testing
- effect of COVID-19 exposure
- Where
- Italy
- Volunteers
- 1,800 people
- Sponsor
- University Hospital of Ferrara
SARS-CoV-2 Infection
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
The purpose of this study is to evaluate the safety of STI-1558 in healthy subjects and the safety, pharmacokinetics, and efficacy in SARS-CoV-2-Positive subjects.
- Trial name
- NCT05523739
- Testing
- STI-1558
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Hip Fractures, COVID-19
Anesthesia Technique in COVID-19 Positive Hip Fracture Patients
Patients with COVID undergoing hip fracture repair have high mortality rates. If spinal anesthesia is associated with decreased rates of mortality, this study could provide hypothesis generating data for prospective studies.
- Conditions
- Hip Fractures, COVID-19, General Anesthesia, Spinal Anesthesia
- Trial name
- NCT05133648
- Testing
- Hip Fracture Surgery, COVID-19 infection
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
COVID-19, COVID
COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI)
COVID-19 infection is currently confirmed by a complex, multiple-step procedure starting with a mucosal swab, followed by viral RNA extraction and processing and qPCR.
- Conditions
- COVID-19, COVID, SARS-CoV 2
- Trial name
- NCT04756518
- Where
- United Kingdom
- Volunteers
- 215 people
- Sponsor
- East Suffolk and North Essex NHS Foundation Trust
COVID-19
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Evidence has shown that COVID-19 infections can lead to an increased risk of blood clots. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death.
- Trial name
- ETHIC (NCT04492254)
- Testing
- Enoxaparin
- Where
- 3 sites in Australia, Belgium and 1 more
- Volunteers
- 219 people
- Sponsor
- Thrombosis Research Institute
Covid19
Sitagliptin Treatment in Diabetic COVID-19 Positive Patients
Coronavirus Pathology is frequently associated with both diabetes mellitus and metabolic syndrome. In particular, results of observational studies and meta-analyzes configure diabetes as one of the main risk factors for the…
- Trial name
- SIDIACO-RETRO' (NCT04382794)
- Testing
- Retrospective case-control analysis
- Where
- 6 sites in Italy
- Volunteers
- 338 people
- Sponsor
- University of Milan
Cytokine Release Syndrome, COVID19
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS).
- Trial name
- NCT04374149
- Testing
- Therapeutic Plasma Exchange, Ruxolitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Prisma Health-Upstate